Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all their primary and secondary endpoints.
Read More
